Dr Jan Přeček reviews recommendations and safety considerations for lowering LDL-C levels


In this clinical topic discussion, Dr. Jan Přeček reviews recommendations and safety considerations for lowering LDL-C levels. Watch the video summary and download the slide set for more information. This educational presentation is relevant for cardiologists and lipidologists, as well as primary care physicians.

Hello on behalf of CORONARY CONNECT: my name is Jan Přeček. I’m a cardiologist from the University Hospital Olomouc in the Czech Republic. I’d like to talk about safety of low levels of LDL cholesterol (LDL-C).

LDL-C as a Risk Factor
Elevated LDL-C is a clearly established major risk factor for the development of atherosclerotic cardiovascular disease.
Risk reduction of atherosclerotic cardiovascular disease is proportional to the absolute and relative LDL-C reduction achieved. In other words, there seems to be no LDL-C threshold, below which no further atherosclerotic cardiovascular disease prevention can be achieved.

Treatment Goals
This is reflected in current guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the Management of dyslipidaemias. Treatment goals for LDL-C were again shifted lower. The use of lipid-lowering drugs in sequential combination is recommended. Intensive lipid-lowering therapy, especially when PCSK9 inhibitors are used, allows very low levels of LDL-C to be achieved.

Supporting Physiological Evidence
But on the other hand, cholesterol plays an important role in human physiology. It’s a key component of many hormones and all cell membranes. So, there has been concern that maintaining LDL-C concentrations at very low levels may also have adverse consequences. I would like to mention two examples on this issue that do not confirm these concerns. The first example is the neonatal period of each of us. The usual level of LDL-C in a newborn is between 0.7 and 1.8 mmol/L. It’s a time of maximum growth acceleration despite low cholesterol levels. So, each of us is a demonstration that low cholesterol does not restrain development.

Supporting Clinical Trial Evidence
The second example includes evidence from trials with intensive lipid-lowering therapy. A meta-analysis from Marc Sabatine published in JAMA Cardiology in 2018 suggests that it’s both safe and effective to lower LDL cholesterol, as low as a median of 0.5 mmol/L. In this study there was no increased risk of adverse outcomes even when LDL was lowered to these levels.

In Summary
So, let me conclude that it’s recommended to lower LDL-C as much as possible to prevent atherosclerotic cardiovascular disease. Achieving very low levels of LDL-C provides an additional clinical benefit reducing the incidence of cardiovascular disease and it’s not associated with serious side effects.

Thank you for your attention on behalf of CORONARY CONNECT.

Dr Jan Přeček is cardiologist at University Hospital Olomouc, Czech Republic. He completed his medical degree and doctoral (Ph.D.) degree at Faculty of Medicine, Palacký University Olomouc. His main areas of clinical focus are acute cardiac care, echocardiography, acute coronary syndromes, heart failure and pulmonary circulation. Dr Přeček has been awarded Fellow of the European Society of Cardiology (FESC). He has participated in multiple clinical trials focused mainly to acute heart failure, antithrombotics, hypolipidemic therapy and pulmonary hypertension.

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Amgen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
CORONARY CONNECT

CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.

Meet the experts

Other programmes of interest

micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Educational Grant from Ipsen.
podcast Podcast

Episode

2

of 2

episode
Rare diseases Pediatrics Endocrinology 
Short stature: Severe primary IGF-I deficiency (SPIGFD) – Episode 2

Diagnosis and management of classical and non-classical forms of primary IGF-I deficiency and overlapping syndromes

Experts
Prof. Andrew Dauber, Prof. Helen Storr
Endorsed by
The Magic Foundation
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Educational Grant from Ipsen.
podcast Podcast

Episode

1

of 2

episode
Pediatrics Endocrinology Rare diseases 
Short stature: Key challenges in diagnosis and management – Episode 1

Video podcast exploring primary IGF-I deficiency, GH deficiency and other rare growth disorders

Experts
Prof. Dr. Joachim Woelfle, Prof. Philippe Backeljauw
Endorsed by
The Magic Foundation
  • download Downloadable
    Resources
  • clock 33 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Educational Grant from Ipsen.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Cardiology 
Heart failure management in the pre- and post-discharge setting: Case study 2

Optimising multiple drugs concurrently

Experts
Prof. Alexandre Mebazaa
  • clock 15 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Educational Grant from Roche Diagnostics.
interactive-patient-case Interactive patient case

Episode

1

of 2

episode
Cardiology 
Heart failure management in the pre- and post-discharge setting: Case study 1

Tolerance of guideline-directed medical therapy (GDMT)

Experts
Prof. Alexandre Mebazaa
  • clock 15 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Educational Grant from Roche Diagnostics.
publication Publication
Oncology Endocrinology 
Acromegaly and Neuroendocrine Tumours Global Survey

Paper published in Advances in Therapy

Endorsed by
Wapo
INCA
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Aug 2023

This educational programme is supported by an Independent Educational Grant from Ipsen.